From lab to field: the path to global reach
Our development journey from foundational research to a tiered global rollout
Rooted in 20+ years of research
Two decades of venom pharmacology and biochemistry research at the University of Reading. Patented combination therapy of repurposed drugs with confirmed freedom to operate
- ✓IP protected
- ✓Built on long-term research into venom pharmacology
Tested against the world's most medically significant snakes
Validated across 70+ venoms globally including vipers, cobras and asps. Provided delay to death in 100% of snakes tested, with protection against 95% of bites in only one dose
- ✓Tested across diverse venom types
- ✓Designed for real-world bites, where the snake is often unknown
Moving into first-in-human trials
Clinical trial plan (CT04) published. Phase I safety studies in healthy volunteers in preparation, followed by Phase II in snakebite patients in high-burden geography
- ✓Trial design approved by Indian regulatory authority (CDSCO)
- ✓Phase I + II trials as per emergency authorisation protocol in India
A regulatory path designed for field realities
A multi-region regulatory plan designed to support early access in high-burden countries, scalable procurement across global health markets, and structured approval in developed healthcare systems
- ✓Prioritising regions with urgent unmet need
- ✓Supporting broad distribution through global health channels
Built to reach where antivenom cannot
Heat-stable oral format means treatment can be stocked in clinics, pharmacies and field kits, not just hospitals with cold chain
- ✓High burden market entry: India-first launch
- ✓Scalable distribution through pharma partner
A path to 125+ countries
Tiered rollout from India into South Asian markets e.g., Bangladesh, Pakistan and Sri Lanka, then Latin America, Africa, Southeast Asia and developed markets
- ✓Phased global expansion
- ✓Staged growth across priority markets